期刊
CURRENT CANCER DRUG TARGETS
卷 20, 期 8, 页码 559-572出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009620666200506110850
关键词
Triple-negative breast cancer; metastasis; chemoresistance; nanocarriers; chemoresistance; drug therapy
类别
资金
- Department of Science and Technology-Fund for Improvement of Science and Technology Infrastructure in Universities and Higher Educational Institutions (DST-FIST), New Delhi [SR/FST/LSI-574/2013]
Triple-negative Breast Cancer (TNBC) is the most aggressive and prevailing breast cancer subtype. The chemotherapeutics used in the treatment of TNBC stiffer from chemoresistance, dose-limiting toxicitics and off-target side effects. As a result, conventional chemotherapeutics are unable to prevent tumor growth, metastasis and result in failure of therapy. Various new targets such as BCSCs surface markers (CD44, CD133, ALDH1), signaling pathways (IL-6/JAK/STAT3, notch), pro and anti-apoptotic proteins (Bcl-2, Bcl-xL, DR4, DR5), hypoxic factors (HIF-1 alpha, HIF-2 alpha) and drug efflux transporters (ABCC1, ABCG2 and ABCB1) have been exploited to treat TNBC. Further, to improve the efficacy and safety of conventional chemotherapeutics, researchers have tried to deliver anticancer agents specifically to the TNBCs using nanocarrier based drug delivery. In this re- view, an effort has been made to highlight the various factors responsible for the chemoresistance in TNBC, novel molecular targets of TNBC and nano-delivery systems employed to achieve site-specific drug delivery to improve efficacy and reduce off-target side effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据